Seth M Pollack
Northwestern University · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Seth M Pollack as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:41 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT07261657 · N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular TherapySeth Pollack · recruiting · Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma · principal investigator
- Ph3NCT06422806 · Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasNational Cancer Institute (NCI) · recruiting · Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMVR01CA298377 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2025 to 2026 · $652,313 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma ModelR01CA290719 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2025 to 2026 · $657,844 awarded in 2026Same name and institution; not confirmed by an ID
- Novel IL-12 Gene Delivery Vehicles for Transformation of Solid TumorsR01CA244872 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2020 to 2024 · $466,837 awarded in 2024Same name and institution; not confirmed by an ID
- Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer PatientsR21CA277285 · NCI · NORTHWESTERN UNIVERSITY · fiscal years 2023 to 2024 · $177,650 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA060553 · NCI · NORTHWESTERN UNIVERSITY · PI Aleksandar Zafirovski · fiscal years 2015 to 2026Named on NCT07261657
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2015 to 2026Named on NCT06422806
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:41 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 279 citationsRCR 29.8
- Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.JAMA Oncol · 2020133 citationsRCR 5.2
- First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.Clin Cancer Res · 201979 citationsRCR 2.6
- A contemporary large single-institution evaluation of resected retroperitoneal sarcoma.Ann Surg Oncol · 201464 citationsRCR 2.3
- Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.J Clin Oncol · 202250 citationsRCR 3.1
- A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.Clin Cancer Res · 202237 citationsRCR 2.6
- 31 citationsRCR 1.2
- 31 citationsRCR 2.4
- IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.J Immunother Cancer · 202117 citationsRCR 0.7
- Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial.Ophthalmic Surg Lasers Imaging Retina · 201814 citationsRCR 0.9